A systematic review synthesizing 20 methylome-wide association studies of substance use disorders in postmortem human brain tissue has identified 525 genes showing differential DNA methylation across independent results from at least two substances. Conducted on behalf of the Psychiatric Genetics Consortium Substance Use Disorders Epigenetics Working Group, the cross-substance analysis revealed shared methylomic signals that may reflect common neurobiological pathways, downstream biological adaptations to substance exposure, or unmeasured polysubstance use.
The systematic review evaluated methylome-wide association investigations conducted across diverse substance classes in human brain tissue. The compiled body of evidence encompassed nine studies examining alcohol, four investigating opioids, three evaluating cocaine, two focusing on nicotine, one addressing methamphetamine, and one assessing any illicit drug.
Substance use disorders represent complex psychiatric conditions influenced by genetic and environmental factors. Within this framework, DNA methylation operates as a dynamic and context-dependent epigenetic mechanism capable of offering biological insight into regulatory variation associated with substance use disorders, particularly when investigated within brain regions central to addiction-related neurobiology.
The analyzed studies exhibited substantial methodological heterogeneity, varying in the specific brain regions analyzed, the methylation profiling platforms employed, and individual sample characteristics. Across the reviewed literature, the majority of investigations concentrated specifically on DNA methylation occurring at cytosines followed by guanine, denoted as mCGs.
Despite the methodological differences and limited overlap of findings within individual substance categories, consistent biological themes emerged across multiple substances. The differentially methylated genes were consistently linked to neurodevelopmental processes, inflammatory responses, cellular signaling, and transcriptional regulation in human brain tissue.
Building upon the convergent epigenetic findings, the investigators conducted exploratory drug repurposing analyses centered on genes that overlapped across three or more substance classes. This evaluation identified a small number of existing pharmaceutical compounds with potential relevance for treating polysubstance use.
The authors highlighted several critical challenges currently limiting methylome-wide association studies of substance use disorders in human brain tissue, including small sample sizes, constrained generalizability, a lack of cell-type specificity, and an absence of functional validation. To advance mechanistic understanding and translational potential, the review concluded that future investigations must prioritize multi-omic integration, larger and more diverse cohorts, and advanced technological platforms.
Subject of Research: DNA methylation patterns in postmortem human brain across substance use disorders
Article Title: A systematic review of substance use disorder methylome-wide association studies in postmortem human brain
Article References: White, J. D., Zillich, L., Zillich, E., Sosnowski, D. W., Foo, J. C., Walss-Bass, C., Lohoff, F. W., Stratford, J. K., Edenberg, H. J., Montalvo-Ortiz, J. L., Maher, B. S., Clark, S. L., & On behalf of the Psychiatric Genetics Consortium Substance Use Disorders Epigenetics Working Group (2026). A systematic review of substance use disorder methylome-wide association studies in postmortem human brain. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04375-x
Image Credits: AI Generated
DOI: 10.1038/s41398-026-04375-x
Keywords: substance use disorders, DNA methylation, methylome-wide association studies, postmortem human brain, epigenetics, alcohol use disorder, opioid use disorder, cocaine, nicotine, methamphetamine, polysubstance use, neurodevelopment, inflammatory response, transcriptional regulation, cell-type specificity, drug repurposing, mCGs, psychiatric genetics
News Source: Cassandra Pierce. (November 15, 2026). Review Identifies 525 Shared Brain Methylation Genes Across Substance Use Disorders. Scienmag.



